Abstract:Objective To evaluate the effectiveness and safety of terazosin in the treatment of Chinese benign prostatic hyperplasia (BPH) patients. Methods A multicenter prospective postmarketing observational study was conducted from June 2007 to March 2008 in 32 urologic centers.Patients were given terazosin for 4 weeks according to the routine medical care procedures following instructions. Effectiveness evaluation included the primary endpoint focusing on the changes in IPSS total score at the end of 2nd and 4th week compared with the baseline. The secondary endpoints were the changes in Qmax and QOL at the end of 4th week, diastolic and systolic blood pressures at the end of 2nd and 4th week compared with the baseline and the discontinuation rate of terazosin within the four weeks. Safety was assessed by adverse events. Results There were 1006 patients included in this study (FAS) and 992 patients (PP) completed the study. Among them, there were 344 patients having hypertension. The total IPSS score reduced from 22.32±6. 13 at baseline to 16. 98±5.92 at the end of the 2nd week and to 14.00±5. 52 at the end of the 4th week in FAS population (P＜0. 01).The total IPSS score changed from 22.32±6.15 at baseline to 16. 96±5.93 at the end of the 2nd week and to 13. 95±5.52 at the end of the 4th week in the PP population (P＜0.01). The efficacy rate was 26.54% at the 2-week treatment and 60.64% at the 4-week treatment, which was defined as obtaining improvement by 30% compared with the baseline. Patient's IPSS in different age groups with different prostatic hyperplasia levels and patients combined with or without 5-α reductase inhibitors were all decreased significantly(P＜0.01). With 4-week treatment of terazosin, Qmax and QOL were improved significantly by 32% and 45% (P＜0.01). Terazosin decreased BPH patient blood pressure with untreated or uncontrolled hypertension (P＜0.05), but had little influence on normal blood pressure of those under control. The incidence of adverse reactions was low. The most common adverse event was dizziness (3.68%). At the end of the study, 960 subjects (95%) were taking drug continuously.Conclasions Terazosin can significantly improve the symptoms and quality of life in Chinese BPH patients with good safety and compliance.

Double Blind Randomized Multicenter Clinical Study on Doxazosin Mesylate for Treatment of Hypertension

CLINICAL TRIAL OF DOXAZOSIN MESYLATE ON THE TREATMENT OF MILD AND MODERATE PRIMARY HYPERTENSION

Clinical Study of Olmesartan/hydrochlorothiazide Compound Tablet in Mild to Moderate Essential Hypertensive Patients Who Did Not Reach Goal with Olmesartan

[A Randomized, Double-Blind, Double-Dummy Study Comparing a Fixed Dose Combination of Telmisartan 80 Mg Plus Hydrochlorothiazide 12.5 Mg to Telmisartan 80 Mg in Chinese Hypertensive Patients Who Failed to Respond Adequately to Telmisartan 80 Mg].

Comparison of the Efficacy and Tolerance of Moxonidine with Enalapril in Mild to Moderate Essential Hypertension

Evaluation of Efficacy of Atenolol and Diltiazem-Sr in the Treatment of Hypertension

Efficacy Comparison Between 5 Mg Perindopril Arginine Salt and 4 Mg Perindopril Tert-Butylamine Salt for Patients with Mild to Moderate Essential Hypertension

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

Efficacy and Safety of Torasemide in Patients with Mild to Moderate Essential Hypertension

A multicenter prospective clinical study on the effectiveness and safety of terazosin in the treatment of Chinese benign prostatic hyperplasia patients

Efficacy Of Combined Amlodipine/Terazosin Therapy In Male Hypertensive Patients With Lower Urinary Tract Symptoms: A Randomized, Double-Blind Clinical Trial

Doxazosin Gastrointestinal Therapeutic System Versus Tamsulosin for the Treatment of Benign Prostatic Hyperplasia: a Study in Chinese Patients.

Clinical efficacy of a short-term regimen of cardura XL on lower urinary tract symptoms and international prognostic scoring system in the treatment of benign prostatic hyperplasia

Efficacy and Safety of Olmesartan Medoxomil in Patients with Mild to Moderate Essential Hypertension

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

Terazosin treatment in BPH/LUTS: a prospective, randomized, multicenter study

Multicentre Clinical Trial on Moxonidine Hydrochloride for Treatment of Hypertension

[Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Chinese Patients with Mild to Moderate Essential Hypertension].

Efficacy and Safety of Domestic Olmesartan in Treatment of Mild to Moderate Essential Hypertension

Effects and safety of mild and moderate primary hypertension treated with olmesartan medoxomil tablet

Clinical Observation on efficacy and safety of Telmisartan hydrochlorothiazide and Telmisartan in patients with Mild to Moderate Essential hypertension